IL296788A - Isotopically labeled trepidil histories - Google Patents

Isotopically labeled trepidil histories

Info

Publication number
IL296788A
IL296788A IL296788A IL29678822A IL296788A IL 296788 A IL296788 A IL 296788A IL 296788 A IL296788 A IL 296788A IL 29678822 A IL29678822 A IL 29678822A IL 296788 A IL296788 A IL 296788A
Authority
IL
Israel
Prior art keywords
compound
therapeutic agent
solvate
pharmaceutically acceptable
crystal
Prior art date
Application number
IL296788A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Publication of IL296788A publication Critical patent/IL296788A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL296788A 2020-03-26 2021-03-25 Isotopically labeled trepidil histories IL296788A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000347P 2020-03-26 2020-03-26
US202063063846P 2020-08-10 2020-08-10
PCT/US2021/024226 WO2021195425A1 (en) 2020-03-26 2021-03-25 Isotopically-labelled trapidil derivatives

Publications (1)

Publication Number Publication Date
IL296788A true IL296788A (en) 2022-11-01

Family

ID=77892379

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296788A IL296788A (en) 2020-03-26 2021-03-25 Isotopically labeled trepidil histories

Country Status (10)

Country Link
US (1) US12508267B2 (enExample)
EP (1) EP4125853A4 (enExample)
JP (2) JP7730336B2 (enExample)
KR (1) KR20230013023A (enExample)
CN (3) CN115916180A (enExample)
AU (1) AU2021244241A1 (enExample)
CA (1) CA3177066A1 (enExample)
IL (1) IL296788A (enExample)
MX (1) MX2022011879A (enExample)
WO (1) WO2021195425A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176652A2 (en) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
CN115916180A (zh) 2020-03-26 2023-04-04 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
AU661080B2 (en) 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
KR100291362B1 (ko) 1992-10-16 2001-09-17 니뽄 신야쿠 가부시키가이샤 왁스매트릭스의제법
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
CA2685524A1 (en) * 2007-04-30 2008-11-06 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
AU2009237570B2 (en) 2008-04-18 2014-11-06 Stephen Dodd Magnetic microstructures for magnetic resonance imaging
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059113A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
US11281170B2 (en) 2015-12-29 2022-03-22 Jones And Malterer Technology Innovations Incorporated Multi-point synchronizable and scalable lighting control systems
WO2017176652A2 (en) * 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JOP20200187A1 (ar) * 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CA3163242A1 (en) 2019-12-02 2021-06-10 Aarash BORDBAR Treating cognitive disorders using trapidil
CN115916180A (zh) 2020-03-26 2023-04-04 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
WO2021262786A1 (en) 2020-06-24 2021-12-30 Yale University Pank modulators and methods using same

Also Published As

Publication number Publication date
CN115916180A (zh) 2023-04-04
CN116496279B (zh) 2025-12-12
US12508267B2 (en) 2025-12-30
JP2023519289A (ja) 2023-05-10
CN121550230A (zh) 2026-02-24
JP7730336B2 (ja) 2025-08-27
MX2022011879A (es) 2023-01-11
JP2025183224A (ja) 2025-12-16
AU2021244241A1 (en) 2022-11-24
CA3177066A1 (en) 2021-09-30
KR20230013023A (ko) 2023-01-26
US20230102580A1 (en) 2023-03-30
TW202202502A (zh) 2022-01-16
EP4125853A4 (en) 2024-07-03
EP4125853A1 (en) 2023-02-08
TW202547838A (zh) 2025-12-16
CN116496279A (zh) 2023-07-28
WO2021195425A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US11643390B2 (en) Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses
CN112479996B (zh) 吡啶氮氧化合物及其制备方法和用途
JP2025183224A (ja) 同位体標識トラピジル誘導体
TWI537263B (zh) 使用作為β－分泌酶抑制劑之５，６－二氫－２Ｈ－［１，４］－３－基－胺衍生物
KR20140008297A (ko) 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
US11708376B2 (en) Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers
JP2022533433A (ja) ［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミンの薬学的に許容される塩、およびその使用
EP3630115A1 (en) Compositions and methods for preparing and using mitochondrial uncouplers
JP2025514548A (ja) カレバスチンの塩及びその用途
JP2018530612A (ja) パーキンソン病の治療のための重水素化レボドパとカルビドパおよびオピカポンとの組合せ
WO2024261234A1 (en) Deuterated analogs of sirtuin 6 modulator imu-856
TWI917367B (zh) 經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途
TWI918457B (zh) 經同位素標記之曲匹地(trapidil)衍生物
WO2015092720A1 (en) Metabolites of sonidegib (lde225)
EP4221698A1 (en) Combination drug substance of polyamine transport inhibitor and dfmo
HK40090744A (zh) 同位素标记的曲匹地尔衍生物
CN120736994B (zh) 氯胺酮衍生物及其在精神疾病的治疗中的用途
US20260092037A1 (en) Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
JPH05504765A (ja) 神経学的疾患を治療するための４，４′―〔９ｈ―フルオレン―９―イリデンビス（メチレン）〕ビスピリミジン
US3179564A (en) Antirigor thioxanthenes
CN119896673A (zh) Glp-1r激动剂与二甲双胍在制备治疗糖尿病及其并发症药物中的应用
HK40063249B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
JPH0374673B2 (enExample)
NZ617347A (en) Pentylenetetrazole derivatives